Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.42 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.42 |
| ▸ | BAD | Q92934 | 1/20 | 0.42 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PRF1 | P14222 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 2/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1134044 | 1.00 | BCL2 (0.42) | BCL2BCL2L2BADAADATMAPT | |
| SCHEMBL13587033 | 0.92 | AADAT (0.46) | BCL2BCL2L2BADAADATMAPT | |
| SCHEMBL1133685 | 0.89 | BCL2L2 (0.52) | BCL2BCL2L2BADMAPTPTPN1 | |
| SCHEMBL13587018 | 0.89 | BCL2L2 (0.52) | BCL2BCL2L2BADMAPTPTPN1 | |
| SCHEMBL1133775 | 0.89 | PRF1 (0.49) | BCL2BCL2L2BADAADATMAPT | |
| SCHEMBL13587022 | 0.89 | PRF1 (0.49) | BCL2BCL2L2BADAADATMAPT | |
| SCHEMBL4377150 | 0.89 | BCL2L2 (0.52) | BCL2BCL2L2BADMAPTPTPN1 | |
| SCHEMBL1133776 | 0.89 | PRF1 (0.49) | BCL2BCL2L2BADAADATMAPT | |
| SCHEMBL1133612 | 0.85 | PRF1 (0.49) | BCL2BCL2L2BADMAPTKMT2A | |
| SCHEMBL1133613 | 0.85 | PRF1 (0.49) | BCL2BCL2L2BADMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2285802-B1 | OXO-IMIDAZOLYL COMPOUNDS HAVING ANTIBACTERIAL ACTIVITY | ASTEX PHARMACEUTICALS INC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-8759384-B2 | Oxo-imidazolyl compounds | ASTEXPHRMACEUTICALS, INC. | 2014-06-24 | — | — | US | disclosed |
| US-20090298900-A1 | Oxo-Imidazolyl Compounds | ASTEXPHRMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298900-A1 | Oxo-Imidazolyl Compounds | GALE, CYP51A1, GNE | BCL2 3457/4885BCL2L2 3036/4885BAD 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.